BRAF V600E is a possible biomarker for risk stratification and prognostication in papillary thyroid carcinoma. Studies on its association with aggressive clinicopathological features among East Asian populations are limited. This study examines the clinical and histopathological features of this mutation in Filipinos with conventional papillary thyroid carcinoma. Methods: Formalin-fixed, paraffin embedded thyroid tissue blocks of papillary carcinoma for the study period January 2010 to December 2012 were retrieved. Slides were reviewed and described according to tumour size, variant type, sclerosis, multifocality, subcapsular location, extra-thyroidal extension, nodal metastasis, and nodal extracapsular spread. Medical records were reviewed...
The BRAF p.V600E mutation represents the most specific marker for papillary thyroid carcinoma and is...
BACKGROUND: Although several studies undoubtedly demonstrated that BRAF mutation is an important gen...
Papillary thyroid cancer (PTC) constitutes more than 90 % of the thyroid cancers. MAP kinase/ERK pat...
The aim of this study was to investigate the association between the BRAF V600E mutation incidence a...
Objective Papillary thyroid carcinoma (PTC) accounts for 95% of all thyroid carcinomas. PTC is an ep...
Background: The BRAF mutation has been shown to be associated with aggressive clinicopathologic char...
In this study, BRAF mutation was found in 219 of 500 cases (43.8%). In particular, we found the most...
Mutation of the BRAF gene is common in thyroid cancer. Follicular variant of papillary thyroid carci...
Abstract CONTEXT: Because very few studies have examined the correlation between BRAF mutations an...
ABSTRACT Objectives: We aimed to investigate the prevalence of the BRAF (V600E) mutation in consecu...
The mutation BRAF V600E is thought to be a putative prognostic marker of the aggressiveness of sever...
Thyroid nodules are detected in about 50% of adults who live in regions deficient in iodine. Althoug...
: The BRAF p.V600E mutation represents the most specific marker for papillary thyroid carcinoma and ...
BRAF((V600E)) mutation is the most frequent genetic alteration in papillary thyroid carcinomas (PTCs...
BACKGROUND: Papillary thyroid cancers often occur as multiple foci. Multifocal cancers have been con...
The BRAF p.V600E mutation represents the most specific marker for papillary thyroid carcinoma and is...
BACKGROUND: Although several studies undoubtedly demonstrated that BRAF mutation is an important gen...
Papillary thyroid cancer (PTC) constitutes more than 90 % of the thyroid cancers. MAP kinase/ERK pat...
The aim of this study was to investigate the association between the BRAF V600E mutation incidence a...
Objective Papillary thyroid carcinoma (PTC) accounts for 95% of all thyroid carcinomas. PTC is an ep...
Background: The BRAF mutation has been shown to be associated with aggressive clinicopathologic char...
In this study, BRAF mutation was found in 219 of 500 cases (43.8%). In particular, we found the most...
Mutation of the BRAF gene is common in thyroid cancer. Follicular variant of papillary thyroid carci...
Abstract CONTEXT: Because very few studies have examined the correlation between BRAF mutations an...
ABSTRACT Objectives: We aimed to investigate the prevalence of the BRAF (V600E) mutation in consecu...
The mutation BRAF V600E is thought to be a putative prognostic marker of the aggressiveness of sever...
Thyroid nodules are detected in about 50% of adults who live in regions deficient in iodine. Althoug...
: The BRAF p.V600E mutation represents the most specific marker for papillary thyroid carcinoma and ...
BRAF((V600E)) mutation is the most frequent genetic alteration in papillary thyroid carcinomas (PTCs...
BACKGROUND: Papillary thyroid cancers often occur as multiple foci. Multifocal cancers have been con...
The BRAF p.V600E mutation represents the most specific marker for papillary thyroid carcinoma and is...
BACKGROUND: Although several studies undoubtedly demonstrated that BRAF mutation is an important gen...
Papillary thyroid cancer (PTC) constitutes more than 90 % of the thyroid cancers. MAP kinase/ERK pat...